

 <p><b>St. Charles Health System</b> Adult Ambulatory Infusion Order Lecanemab (LEQEMBI)</p>	<p>Patient Name: Date of Birth: <i>Patient Identification</i></p>
<p><b>ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK ( ✓ ) TO BE ACTIVE</b></p>	
<p>Treatment Start Date: _____ Allergies: _____  Weight: _____ kg Height: _____ cm</p> <p><b>REQUIRED ITEMS for all orders – necessary for insurance approval, scheduling, and patient safety</b></p> <ol style="list-style-type: none"> <li><b>1. FACE SHEET with complete INSURANCE information and patient CONTACT information</b></li> <li><b>2. Recent VISIT NOTE to support treatment (if not available in Epic)</b></li> <li><b>3. LAB RESULTS for any required prescreening (if not available in Epic)</b></li> <li><b>4. DIAGNOSIS CODE _____</b></li> <li><b>5. Patient NAME and DATE OF BIRTH on EVERY page faxed</b></li> </ol>	

**GUIDELINES FOR ORDERING**

1. Confirm the presence of amyloid beta pathology prior to initiating treatment (e.g. CSF assessment or PET scan).
2. Obtain a recent (within one year) brain MRI prior to initiating treatment to evaluate for pre-existing Amyloid Related Imaging Abnormalities (ARIA).
3. Obtain an MRI prior to the 3rd, 5th, 7th, and 14th infusions. If radiographically observed ARIA occurs, treatment recommendations are based on type, severity, and presence of symptoms.
4. Enhanced clinical vigilance for ARIA is recommended during the first 14 weeks of treatment with lecanemab. If patient experiences symptoms suggestive of ARIA, clinical evaluation should be performed, including MRI if indicated. If ARIA is observed on MRI, careful clinical evaluation should be performed prior to continuing treatment.
5. Apolipoprotein E (ApoE ε4) genotyping should be assessed prior to treatment initiation and inform risk for development of ARIA.

**NURSING ORDERS:**

1. Monitor for infusion reactions during infusion and observe for at least 1 hour after completion of first two infusions. The highest incidence of infusion reactions occurs with the first infusion.
2. Confirm an MRI was performed prior to the 3rd, 5th, 7th, and 14th infusions.
3. Hold infusion and notify provider if patient reports: Headache, dizziness, vision changes, or new/worsening confusion.
4. Follow facility policies and/or protocols for vascular access maintenance with appropriate flush solutions, declotting (alteplase), and/or dressing changes.

**PRE-MEDICATIONS:** (Administer 30 minutes prior to infusion)

**Note to provider: Please select which medications below, if any, you would like the patient to receive prior to treatment by checking the appropriate box(s)**

- Acetaminophen (TYLENOL) tablet, 650 mg, oral, ONCE AS NEEDED IF PATIENT HAD PRIOR INFUSION REACTION, every visit



**St. Charles Health System**

Adult Ambulatory Infusion Order  
Abatacept (ORENCIA)

Patient Name:

Date of Birth:

*Patient Identification*

**ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK ( ✓ ) TO BE ACTIVE**

- DiphenhydrAMINE (BENADRYL) capsule, 25 mg, oral, ONCE AS NEEDED IF PATIENT HAD PRIOR INFUSION REACTION every visit. Give either diphenhydrAMINE or loratadine, not both.
- Loratadine (CLARITIN) tablet, 10 mg, oral, ONCE AS NEEDED IF PATIENT HAD PRIOR INFUSION REACTION and diphenhydrAMINE is not given, every visit. Give either loratadine or diphenhydrAMINE, not both.
- Dexamethasone (DECADRON), 10 mg, intravenous, ONCE AS NEEDED IF PATIENT HAD PRIOR INFUSION REACTION, every visit.

**MEDICATIONS:**

- Lecanemab (LEQEMBI), 10 mg/kg in sodium chloride 0.9% 250 mL, intravenous, ONCE, over 1 hour, every 2 weeks.

**INFUSION MONITORING/REACTION:**

Infusion Reaction. Acute Infusion and Hypersensitivity Medication Protocol will be used unless the provider selects the option below. If opting out, alternative orders must be included.

1. diphenhydramine 25 mg IV, AS NEEDED x1 for hypersensitivity reaction
2. famotidine 20 mg IV, AS NEEDED x1 dose for hypersensitivity reaction
3. methylprednisolone 125 mg IV, AS NEEDED x1 dose for hypersensitivity reaction
4. epinephrine 0.3 mg IM, AS NEEDED x1 dose for hypersensitivity reaction
5. sodium chloride 0.9% 1000 mL IV, 200 mL/hr, AS NEEDED x 1 dose for alteration in hemodynamic status
6. albuterol 2.5 mg/3 mL nebule, AS NEEDED x1 dose for hypersensitivity reaction

- Opting out of standard protocol. Alternative orders are attached, or deviations are documented:

Patient will be treated at the following infusion location:

- St. Charles Outpatient Infusion Center  
2500 NE Neff Road, Bend, OR 97701  
Phone: (541) 706-5820 Fax: (541) 706-5825

By signing below, I represent the following:

- I am responsible for the care of the patient identified on this form
- I hold an active, unrestricted license to practice medicine
- I am acting within my scope of practice and authorized by law to order the medication described above for the patient identified on this form

**ALL ITEMS BELOW MUST BE COMPLETED TO BE A VALID PRESCRIPTION**



**St. Charles Health System**

Adult Ambulatory Infusion Order  
Abatacept (ORENCIA)

Patient Name:  
Date of Birth:

*Patient Identification*

**ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK ( ✓ ) TO BE ACTIVE**

Signature: \_\_\_\_\_ License #: \_\_\_\_\_ Date: \_\_\_\_\_

Print Name: \_\_\_\_\_ Phone: \_\_\_\_\_ Fax: \_\_\_\_\_

**Plan will expire 1 year after signature date at which time a new order will need to be placed**